Current Report Filing (8-k)
12 August 2016 - 10:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 12, 2016
PRONAI THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-37490
|
|
20-0138994
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
2150 885 West Georgia Street
Vancouver, British Columbia, Canada
|
|
V6C 3E8
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(604) 558-6536
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On August 12, 2016, ProNAi Therapeutics, Inc. (the
Company) reported its financial results for the quarter ended June 30, 2016. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this report.
The information furnished with Item 2.02 of this report, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the
Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 9.01.
|
Financial Statements and Exhibits.
|
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Press release dated August 12, 2016.
|
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
PRONAI THERAPEUTICS, INC.
|
|
|
|
|
Date: August 12, 2016
|
|
|
|
By:
|
|
/s/ Sukhi Jagpal
|
|
|
|
|
|
|
Sukhi Jagpal
|
|
|
|
|
|
|
Chief Financial Officer
|
3
EXHIBIT INDEX
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Press release dated August 12, 2016.
|
4
Sierra Oncology (NASDAQ:SRRA)
Historical Stock Chart
From Apr 2024 to May 2024
Sierra Oncology (NASDAQ:SRRA)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Sierra Oncology Inc (NASDAQ): 0 recent articles
More Pronai Therapeutics Inc News Articles